European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas

European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN, +1.42%   AZN, -1.26% said it’s pay...

Netflix, Workday, Costco, Caterpillar and more: These stocks are Cowen’s favorites for 2023

Across the market, Cowen & Co. analysts see undervalued stocks. They rolled out their individual best picks late in the week, highlighting their takes on compelling plays in healthcare, technology...

Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023

Clovis Oncology Inc. shares CLVS, -71.62% plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company ...

LogicBio’s stock skyrockets after buyout bid for a 667% premium

Shares of LogicBio Therapeutics Inc. LOGC, +644.44% skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session’s record low, after the genetic medicine com...

Gilead’s stock is up about 4% after sharing new data for cancer drug

Shares of Gilead Sciences Inc. GILD, +5.16% were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic...

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...